ducovest

SPXT:ARCA-ProShares S&P 500 Ex-Technology

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 56.308

Change

-0.07 (-0.13)%

Market Cap

USD 2.22M

Volume

2.60K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks investment results, before fees and expenses that track the performance of the S&P 500? Ex-Information Technology & Telecommunication Services Index (the "index"). Under normal circumstances, the fund will invest at least 80% of its total assets in component securities. The index seeks to provide exposure to the companies of the S&P 500? Index (the "S&P 500?") with the exception of those companies included in the Information Technology and the Telecommunication Services Sectors (collectively, the "Technology Sector").

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 22/09/2015

Primary Benchmark: S&P 500 Ex-Infor Tech USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.27%

Management Expense Ratio: 0.27 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
CVE Cenovus Energy Inc 1.43 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

-0.12 (-0.23%)

 N/A

ETFs Containing SPXT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.12% 49% F 67% D+
Dividend Return 0.95% 85% B 28% F
Total Return 19.07% 49% F 64% D
Trailing 12 Months  
Capital Gain 6.48% 50% F 72% C
Dividend Return 1.92% 85% B 36% F
Total Return 8.40% 53% F 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 6.51% 49% F 59% D-
Dividend Return 7.64% 40% F 57% F
Total Return 1.13% 39% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 7.17% 71% C- 92% A
Risk Adjusted Return 106.58% 60% D- 94% A
Market Capitalization 2.22M 15% F 3% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.